I've asked you and others the question I wanted to ask. Why not try to explain?
Why do you suppose that the Company chose to limit the distribution of the news that Brilacidin has a feature that "distinguishes it from all other known anti-SARS-CoV-2 drug candidates in development" to a Shareholder Alert?
Assuming that Brilacidin has such a feature I would expect this CEO to be shouting it from a rooftop, wouldn't you?
If the question truly raises doubt as to the veracity of what was communicated in the shareholder alert all the more reason to answer it. At least TRY.